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Introduction
Diffuse Large B-Cell Lymphoma (DLBCL) is the 
most often found lymphoma subtype (31%) 
of all Non-Hodgkin Lymphoma (LNH). This 
lymphoma is a unique lymphoid malignant 
disease because it has different characteristics 
ranging from clinical symptoms, morphology, 
immunology, and molecular phenotypes 
that can affect the treatment and prognosis 
of the disease.1 The LNH is predominantly 
occurred at a productive age around 45–64 
years old and histologically, DLBCL is the most 
prevalent. Interestingly, there is a correlation 
between gender, age and clinical diagnosis 
with histological type lymphoma.2
The national basic health research (Riset 
Kesehatan Dasar, RISKESDAS) conducted by 
the Ministry of Health Republic of Indonesia in 
2013 has shown that the Yogyakarta Province 
has the highest prevalence of lymphoma, 
and the West Java Province has the highest 
estimated number of lymphoma patients with 
almost 3,000 patients.3 The diagnosis of DLBCL 
is obtained from history, physical examination, 
routine blood tests, plain chest X-ray, and 
Computed Tomography (CT) of the head 
and neck. Establishing a definite diagnosis 
of DLBCL is obtained from histopathological 
examination of biopsy tissue in nodules or 
tumors in the head region of the neck, and 
the prognosis of DLBCL can be observed with 
the International Prognostic Index Score (IPI 
Score).4
Nearly two decades ago, LDH is the only 
biological parameter included in the IPI score 
for DLBCL. Some studies report the percentage 
of DLBCL patients with an increase in serum 
lactate dehydrogenase (LDH) levels which is 
relatively low, ranging from 10.2% to 37%. 
Therefore, new tumor markers are needed as 
an indicator of disease activity in evaluating 
treatment success.5 Interestingly, high 
expression of cancer antigen 125 (CA-125) 
serum levels has been found in LNH patients. 
DLBCL patients with high CA-125 serum levels 
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Background: Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of the Non-
Hodgkin Lymphoma (LNH). Until now, lactate dehydrogenase (LDH) is the only tumor marker to assess 
DLBCL progression; however, increased LDH is a relatively non-specific biomarker. Cancer antigen 
125 (CA-125) serum level have been used as a tumor marker in ovarian cancer. The aim of this study 
was to explore the possible role of CA-125 serum level as a tumor marker in head and neck DLBCL.
Methods: This was an observational descriptive study among consecutively sampled DLBCL patients. 
CA-125 serum level examination was carried out (ADVIA Centaur CA-125II) and described along with 
the clinical characteristics of DLBCL patients.
Results: DLBCL was mostly observed in males (54.05%), most often in the 55-65 year age group 
(51.3%), with stage 1 DLBCL was the most prevalent (71.9%). The mean CA-125 serum level was 22.9 
U/ml and increased in patients with advanced DLBCL.
Conclusions: Increased CA-125 serum level in DLBCL, especially at advanced stages, suggests that CA-
125 serum level may be of benefit as a tumor marker in the head and neck DLBCL. Further study is in 
need to explore the role of CA-125.
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have worse prognostic factors at diagnosis, 
higher relapse rates, and worse life expectancy.6 
CA-125 serum level is also significantly higher 
in advanced LNH patients (stage 3 or 4) 
than in the early stages (stage 1 or 2).7 The 
biological information given by CA-125 serum 
is different from other serum markers such as 
levels of LDH released by lymphoma cells. The 
fact that LDH levels provide information about 
the number of tumor cells in the body and 




     Male 20 54.05
     Female 17 45.95
Age (years)
     17–25 1 2.7
     26–35 - -
     36–45 1 2.7
     46–55 9 24.3
     56–65 19 51.3
     ≥65 7 18.9
Stages
     I 27 72.9
     II 5 13.5
     III 3 8.1
     IV 2 5.5
ECOG-PS*
     0 25 67.5
     1 7 18.9
     2 3 8.1
     3 2 5.5
     4 - -
LDH**
     Normal (85–27 U/L) 26 70.2
     >1-3 times normal 9 24.3
     > 3 times normal 2 5.5
IPI Score***
     0–1 30 81
     2 3 8.1
     3 3 8.1
     4 1 2.8
Note: * ECOG-PS:The Eastern Cooperative Oncology Group performance status; ** LDH: lactate dehydrogenase; ***IPI 
score,: International Prognostic Index Score
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lymphoma proliferation activities, whereas 
an increase in CA-125 serum level reflects the 
patient’s response to the potential for tumor 
invasion and provides a measure of infiltration 
activity.8 In light of the fact above, this study 
aimed to explore whether CA-125 serum 
levelscan serve as a tumor markers in the head 
and neck DLBCL. 
Methods
This study was a descriptive observational 
study to determine the CA-125 serum level 
in DLBCL patients. The selection of study 
subjects was conducted by consecutive 
sampling. Patients who fulfilled the inclusion 
and exclusion criteria based on the order of 
patient arrival were recruited. Determination 
of sample size in this study was in accordance 
with the study objectives by using the 
formula for determining the sample size 
for study observational descriptive, a large 
sample formula was used. The minimum 
sample number was 37 subjects. The study 
was conducted at Dr. Hasan Sadikin General 
Hospital Bandung, at the Outpatients Clinic 
of Otolarhyngology Head and Neck Surgery in 
March–August 2018. The protocol of the study 
was approved by the Ethical Committee of Dr. 
Hasan Sadikin General Hosptal Bandung with 
no. LB.04.01/A05/EC/093/III/2018.
The Eastern Cooperative Oncology Group 
(ECOG) performance status (PS), were 
designated as followed: Status 0 Fully active, 
able to carry on all pre-disease performance 
without restriction; Status 1 Restricted in 
physically strenuous activity but ambulatory 
and able to carry out work of a light or 
sedentary nature, e.g., light housework, office 
work; Status 2 Ambulatory and capable of all 
self-care but unable to carry out any work 
activities; up and about more than 50% of 
waking hours; Status 3 Capable of only limited 
self-care; confined to a bed or chair more than 
50% of waking hours; Status 4 Completely 
disabled; cannot carry on any self-care; totally 
confined to bed or chair and Status 5 death. 
The IPI Score was used to determine the 
prognosis. The stage of LNH patients was 
defined as early stages (stage 1 or 2) and late 
stages (stage 3 or 4). CA-125 serum level (U/
mL) was further measured and < 35U/mL was 
the cutoff point value. Results were presented 
in tables in percentages.
Results
Of DLBCL patients included (n=37), male 
(54.05%) was predominantly occurred 
compared to female. The age group of 56-
65 years was the most prevalent (51.3%) 
and stage 1 DLBCL was the most (72.9%) as 
shown in Table 1. Most of the patients had 
ECOG-PS score 0 (67.5%) and predominantly 
had normal LDH level (70.2%), with the IPI 
score 0–1 was the highest (81%). Extranodal 
location was found in 13.5%. Mean value of 
CA-125 serum levels in 37 subjects was 22.9U/
mL (S.D 4.85), and most of them (86.49%) had 
below 35 U/mL serum CA-125 level as shown 
in Table 2.
Discussions
Our results showed more male (54.05%) 
patients were found compared to female 
patients. This result is similar to the 
previous study from 13 hematology centers 
in Indonesia showing that the incidence of 
LNH is slightly more common in male than 
female, with a ratio of 1.6: 1.2.3 Males are 
thought to be at greater risk of LNH because 
of smoking habits, occupational factors, and 
environmental exposure such as pesticides, 
however, studies to identify exposure patterns 
for the incidence of LNH has never been 
done in Indonesia. In Indonesia, farmers, 
forest workers, and agricultural workers are 
mostly men. Potentially dangerous exposures 
among these groups include pesticides that 
contain phenoxy acids, organophosphates, 
organochlorines, benzene, and other organic 
solvents.3
Interestingly, there is also an increase in the 
incidence of LNH based on age. Non-Hodgkin’s 
lymphoma is more common in the productive 
group as shown in this study which is 45–64 
age group. Diffuse Large B-Cell Lymphoma is 
Table 2 Cancer Antigen-125 Serum Level in Diffuse Large B-Cell Lymphoma Patients at 
  Dr. Hasan Sadikin General Hospital 
CA-125 serum levels Number of Subject Proportion
0-34 U/mL 32 86.5%
≥35 U/mL 5 13.5%
Note: cut off point for CA-125 serum level of <35 U/mL
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like most cancers, the disease will increase 
with age, reflecting the damage to DNA of cells 
that accumulates over time. Damage can occur 
due to biological processes or from exposure 
to risk factors. A study clearly shows that there 
is a significant correlation between age and 
histopathology type of lymphoma.2
The mean CA-125 serum level is 22.9 U/mL 
(s.d.4.85); which is below 35 U/mL. Individuals 
with CA-125 serum levels that exceeded cut-off 
≥ 35 U/mL are diagnosed with advanced stage 
DLBCL. This result is following another study 
showing that CA-125 serum level will increase 
beyond the cut-off ≥ 35 U/mL at an advanced 
stage. This study also shows an association 
between high CA-125 serum level and the 
involvement of the lung, pleuro-pericardial or 
mediastinal peritoneum and/or abdomen in 
advanced LNH. An increased serum CA-125 
level with involvement of pleural effusions 
could represent pleuro-peraticardial or 
peritoneal mesothelial cell responses to tumor 
activity. Lymphokine released by advanced 
LNH shows direct involvement by tumor 
activity as the main stimulus for CA-125 
production.9
In this study, in outpatient clinic shows 
that most DLBCL stadium was in stage 1 as 
many as 72.9%. There has been no previous 
study describing the epidemiology of the 
DLBCL stage. This can be estimated that the 
study has been conducted in the outpatient 
clinic. Patients with more advanced stages 
(stage 3 and 4) usually complain about 
diregional lumps other than the head and 
neck, and thus advanced DLBCL patients are 
not expected to visit the Outpatient Clinic of 
Otorhinolaryngology Head and Neck Surgery. 
Moreover, these patients have a good ECOG 
score performance status with a score of 0 is 
the most common since the respondents were 
in earlier stages. Stage is directly proportional 
to ECOG performance status, thus it supports 
the findings of this study that the stage 1 is the 
most prevalent, the ECOG performance status 
score is mostly equal as 0 which is optimal.10
Furthermore, the LDH serum levels were 
found normal for the early stage respondent. 
The LDH associated with several characteristics 
of diseases such as symptoms, tumor size, and 
organomegaly. Lactate dehydrogenase serum 
activity is increased in many cancer patients 
and thus may serve as a prognostic marker.11 
The LDH serum is also found to be involved 
in tumor metabolism. The hallmark of most 
cancer cells is a metabolic change in which 
cancer cells depend on anaerobic respiration 
as the main energy source. This involves the 
production of lactate from glucose under a 
sufficiently oxygenated environment, known 
as the Warburg effect. Therefore, tumor cells 
take excess glucose and use it to accelerate 
growth and replication. Lactate dehydrogenase 
serum generally increases in disorders of 
lymphoid proliferation. In patients with LNH, 
LDH serum levels have prognostic importance 
and thus can be used to monitor treatment 
response and recurrence.11
The results of our study show that the IPI 
score 0–1 is the highest with 81% in the study 
subjects with normal CA-125 serum level, 
having a low risk with a 5-year life expectancy 
of 73%. These results show that based on the 
calculation of the IPI component score of 81% 
of the DLBCL study subjects are found more 
at the age of ≤60 years, stage 1 and 2, normal 
LDH levels, no extranodal locations, and ECOG-
PS 0.
The limitation of this study is that the study 
method is an observational descriptive study, 
therefore, a further correlation between the 
increase in CA-125 serum level and stage, LDH 
level, IPI Score, ECOG-PS on DLBCL on the head 
and neck have not been performed due to lack 
of the study respondents numbers. Further 
study is needed to explore these associations.
In a conclusion, the CA-125 serum levels in 
DLBCL patients in the early stage are normal. 
An increased CA-125 serum level in DLBCL, 
especially at advanced stages suggests that CA-
125 serum levels may be of benefit as a tumor 
marker in the head and neck DLBCL. Further 
study is in need to explore the role of CA-125.  
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